choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Synflorix

Synflorix Newsletter
  • Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine 17 Mar 2025 12:00 GMT

    … Former Chair of GSKโ€™s vaccine business and Chief … deep expertise in drug development and company creation … to investments in big pharma and biotechnology companies. … Rotarixยฎ, and Synflorixยฎ are registered trademarks of GlaxoSmithKline, PLC. Contacts …

  • Pneumococcal Vaccine Global Market Projected to Reach $12.12 Billion by 2029 06 Feb 2025 23:05 GMT

    … for effective vaccines. โ€ข Widespread application of vaccines: The pneumococcal vaccine stimulates the … 1) Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products 2) … Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui …

  • Pneumococcal Vaccine Market Forecast to Surge to US$ 14.43 Billion by 2032, Achieving a Remarkable 6.4% CAGR 10 Jan 2025 13:11 GMT

    … , impacting the pneumococcal vaccine market growth favorably. ๐–๐ก๐จ ๐Œ๐š๐ค๐ž๐ฌ ๐๐ง๐ž๐ฎ๐ฆ๐จ๐œ๐จ๐œ๐œ๐š๐ฅ ๐•๐š๐œ๐œ๐ข๐ง๐ž? โ€ข GSK plc โ€ข Pfizer Inc … โ€ข Pneumococcal conjugate vaccine โ€ข Pneumococcal polysaccharide vaccine By Product Outlook โ€ข Prevnar 13 โ€ข Synflorix โ€ข Pneumovax23 …

  • Navigating the Future: US Pneumococcal Vaccine Market to Sail to US$ 6,511.79 Million by 2034 with a 2.3% CAGR 10 Dec 2024 13:29 GMT

    … Sanofi โ€ข GlaxoSmithKline plc โ€ข CSL Behring โ€ข Serum Institute โ€ข Astellas Pharma US, Inc … 13 โ€ข Synflorix โ€ข Pneumovax23 By Vaccine Type Outlook โ€ข Pneumococcal conjugate vaccine (PCV) … /angina-pectoris-drugs-market Liposomal Doxorubicin Market …

  • Europe Pneumococcal Vaccine Market Set to Boom Anticipating Explosive 5.7% CAGR Growth, Surpass $2.9 Billion by 2032 20 Nov 2024 12:25 GMT

    … ๐ฉ๐ง๐ž๐ฎ๐ฆ๐จ๐œ๐จ๐œ๐œ๐š๐ฅ ๐ฏ๐š๐œ๐œ๐ข๐ง๐ž ๐ฆ๐š๐ซ๐ค๐ž๐ญ ๐ข๐ฌ ๐ฉ๐จ๐ซ๐ญ๐ซ๐š๐ฒ๐ž๐ ๐›๐ฒ ๐œ๐จ๐ฆ๐ฉ๐ž๐ญ๐ข๐ญ๐ข๐ฏ๐ž๐ง๐ž๐ฌ๐ฌ. ๐“๐ก๐ž ๐ญ๐จ๐ฉ ๐ฆ๐š๐ซ๐ค๐ž๐ญ ๐œ๐จ๐ง๐ญ๐ž๐ง๐๐ž๐ซ๐ฌ ๐ฌ๐ฎ๐œ๐ก ๐š๐ฌ: โ€ข Astellas Pharma Inc โ€ข CSL Ltd โ€ข GSK plc โ€ข Merck & Co … Vaccines โ€ข Pneumococcal Polysaccharide Vaccines By Product Outlook โ€ข Prevnar 13 โ€ข Synflorix …

  • Second Stage of Anti-Pneumococcal Vaccination in Las Tunas 01 Nov 2024 20:16 GMT

    … municipalities. โ€œ,โ€ developed by the Finlay Vaccine Institute, protects against seven of … acquire the two commercial vaccines Prevenar 13 and Synflorix, available in the … manufacture. With the Quimi-Vio vaccine, the island gained technological sovereignty …

  • Synflorix 10 Oct 2024 14:23 GMT

    Pneumococcal polysaccharide serotype 23F / Pneumococcal polysaccharide serotype 4 / Pneumococcal polysaccharide serotype 5 / Pneumococcal polysaccharide serotype 6B / Pneumococcal polysaccharide serotype 7F / Pneumococcal polysaccharide …

  • Global Pneumococcal Vaccine Market Set for Robust Expansion, Projected to Reach $11.36 Billion by 2028 09 Jul 2024 11:11 GMT

    … GlaxoSmithKline PLC, and more. These companies are focusing on developing conjugate vaccines … โ€ข Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products โ€ข Route … , Subcutaneous โ€ข Distribution Channel: Pharmacies, Community Clinics, Public Health …

  • Pneumonia Vaccine Market Dynamics: Strategic Analysis and Growth Forecasts by 2032 18 Jun 2024 13:08 GMT

    … pneumonia vaccination. Collaborations and Partnerships: Collaborations between pharmaceutical companies, … Vaccine, and Pneumococcal Polysaccharide Vaccine By Product Type: Prevnar 13, Synflorix … in the Market are: Glaxosmithkline, LG Chem, Merck, …

  • A decade of progress: pneumococcal vaccination vital in protecting Korean children 12 Jun 2024 05:28 GMT

    … the introduction of Synflorix (PCV10) of GSK and Prevenar as … immunized, no preferred vaccine is expected. Instead, proper vaccines will be selected by … of patients in severe cases, vaccination is critical. Pharmaceutical companies, academic societies, and …

Satisfied with the content?

Continue to create your account.